XNAS · CELZ
+40.68% · +$0.2670 · Vol 27.9M
After hours · updated 16:55:49 ET
Creative Medical Technology Holdings, Inc. Common Stock

Creative Medical Technology Holdings, Inc. Common Stock

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
$0.9234
Card
Relationship Map

Veridion Score

BETALOW CONF · 6/6 factorsMethodology
CELZ
Creative Medical Technology Holdings, Inc. Common Stock
Stale score · Tue Aug 4 · completed session · 23h old · Scheduled each trading day · Markets closed · resumes Thu 9:30 ET
SELL BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

30/ 100
Veridion Score
SELL BIAS · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 6/6 factors with data · Stale score · Tue Aug 4 · completed session · 23h old · Scheduled each trading day · Markets closed · resumes Thu 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is CELZ moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading CELZ catalysts
About Creative Medical Technology Holdings, Inc. Common Stock
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2009
Employees
4
Country
US

Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$0.6700
Day high
$0.7049
Day low
$0.6327
Previous close
$0.6564
52W high
$5.59
-83.48% from high
52W low
$0.6327
6% of range
Market cap
$4.3M
EPS
$-0.5100
Beta
1.84
Shares out
6.5M
Volume
27.9M
3.60× rel vol
Avg volume
7.7M
VWAP
$0.9295
Price history computed in-house
1W
+33.44%
1M
-19.70%
3M
-59.68%
1Y
-68.80%
YTD
-52.89%
SMA 50 $1.46 · below
SMA 200 $2.11 · below
52W position 6%

CELZ overview

Veridion Score
30
6 of 6 factors measured
Congress receipts
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around CELZ.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading CELZ Form 4 filings
Public disclosures

Congress activity in CELZ

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for CELZ in the cached public ledger.

Federal contracts

CELZ contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for CELZ in this window.
Lobbying spend

CELZ lobbying filings, year to date.

Registered lobbying filings matched to Creative Medical Technology Holdings, Inc. Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for CELZ in this window.
Loading news for CELZ
Analyst ratings
Sovereign unlock shows live analyst consensus for CELZ.
Options
Sovereign unlock shows live options positioning for CELZ.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.